Uniworth International Limited reported a standalone loss of ₹39.40 lakh for the quarter ended June 30, 2026, compared to a loss of ₹38.81 lakh in the corresponding period of FY25. The company’s consolidated loss widened slightly to ₹39.65 lakh from ₹38.81 lakh in Q1FY25.

The Board of Directors approved the unaudited financial results on August 14, 2026. A critical disclosure in the filing notes that the company’s business activities have been suspended for a long duration, resulting in nil income from operations for both standalone and consolidated entities.

Financial Performance

With no operational revenue generated, the company’s expenses were limited to statutory and administrative overheads. Standalone total expenses rose marginally to ₹39.40 lakh from ₹38.81 lakh in Q1FY25. Finance costs accounted for ₹38.25 lakh of these expenses in both standalone and consolidated figures.

Consolidated expenses totaled ₹39.65 lakh, including a minor contribution from a subsidiary, Uniworth Biotech Limited, which reported a net loss of ₹0.25 lakh and nil revenue. The consolidated loss attributable to owners of the parent was ₹39.10 lakh.

Balance Sheet and Regulatory Notes

The auditor’s review report highlighted several unprovided accounts receivable, including trade receivables of ₹3,010.57 lakh and other financial assets of ₹227.73 lakh. No interest provision was made for borrowings from Punjab National Bank, Indusind Bank, and HSBC Bank, although simple interest provisions were recorded for borrowings from Centurion Bank and Punjab & Sind Bank.

The company has not recognized deferred tax assets due to consistent losses and uncertainty regarding future profits. Additionally, applications have been filed with the Reserve Bank of India for the extension or set-off of certain overdue bills.

Uniworth International Limited reported a consolidated net loss of ₹156.91 lakh for the financial year ended March 31, 2026, narrowing slightly from the loss of ₹157.73 lakh recorded in the previous year. The company's standalone net loss for FY26 stood at ₹157.01 lakh. Total revenue from operations remained nil, while other income for the consolidated entity was reported at ₹0.41 lakh. The Board of Directors approved the audited standalone and consolidated financial results at a meeting held on May 29, 2026.

Khandelwal Ray & Co., the statutory auditor, issued a qualified opinion on the standalone and consolidated financial results. The qualification arises primarily from the non-provision of certain debts and current assets considered doubtful of recovery. Specifically, the auditor noted no provision was made for trade receivables amounting to ₹3,010.57 lakh, other financial assets of ₹227.73 lakh, and loans to body corporates of ₹0.41 lakh. Additionally, no provision was made for an investment of ₹5.12 lakh in a sick and delisted company, TDS receivable of ₹13.95 lakh, and miscellaneous advances of ₹53.39 lakh.

The consolidated financial statements include the results of Uniworth Biotech Limited, a subsidiary acquired during the year. The auditor reported being unable to obtain sufficient appropriate audit evidence regarding the carrying amount of the investment in this subsidiary, amounting to ₹4.93 lakh, due to denied access to financial information and management. Consequently, the auditor could not determine if adjustments were necessary for the subsidiary's net profit of ₹0.07 lakh included in the consolidated results.

Total expenses for the consolidated entity decreased marginally to ₹157.33 lakh in FY26 from ₹157.73 lakh in the previous year. The company's net worth stood at a negative ₹1,202.55 lakh in the consolidated results as of March 31, 2026. Management noted that business activities have been suspended for a long period and that no notional income or expenditure arising from foreign currency gains or losses was accounted for due to uncertainty regarding the realization of export trade receivables. The company has not recognized deferred tax assets in view of consistent losses.

Financial Performance Summary